Employees: 150
Size MedinCell (MEDCL.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.09B, the 132nd largest of 206 France companies the cockpit tracks. Shares closed at €27.66 on 18 Nov 2026.
Performance Over six months the shares gained 3.7%, against -9.7% for the median peer and -2.1% for the France market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 23.2% over the last twelve months (peer median -1.2%); the operating margin is -130.6% (peer median 8.9%).
Valuation It trades at 49.6× enterprise value to sales against a peer median of 2.9× (most expensive of 18).
Next results Next results expected around 9 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €19.5M | €19.5M | €25.4M | €9.03M | €9.89M |
| Revenue growth | — | -23% | +181% | -9% | — |
| EBITDA | -€23.7M | -€23.7M | -€11.2M | -€22.2M | -€26.2M |
| Net income | -€31.3M | -€31.3M | -€18.4M | -€25.0M | -€32.0M |
| Free cash flow | -€25.9M | -€25.9M | €18.4M | -€13.8M | -€26.0M |
| Capital expenditure | €2.04M | €2.04M | €1.66M | €1.19M | €1.03M |
| Total debt | n/a | €57.4M | €58.8M | €59.0M | €57.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MEDCL.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.6% | -1.6% | 9th highest of 21 |
| 6-month return | +3.7% | -9.7% | 6th highest of 20 |
| Distance from 52-week high | -14.6% | -29.8% | 5th highest of 21 |
| Revenue growth (TTM) | -23.2% | -1.2% | 2nd lowest of 17 |
| Operating margin | -130.6% | 8.9% | lowest of 18 |
| EV / Sales | 49.6× | 2.9× | most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 1.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 2.3× | 4.9% | +11.3% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 3.5× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |